Immunomedics, Inc. (NASDAQ:IMMU)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Results 1 - 20 of 30 : 1 2 Next »

Recs

0
Member Avatar TerryFool (35.59) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $3.88 IMMU Score: -7.26

BUY@ 4.0 TP 7

Recs

0
Member Avatar TerryHoodSr (65.85) Submitted: 3/24/2014 6:51:27 PM : Outperform Start Price: $4.07 IMMU Score: -10.48

SPEC BUY@ 4.1 TP 7

Recs

0
Member Avatar richienorker (< 20) Submitted: 9/27/2013 11:29:32 AM : Outperform Start Price: $6.29 IMMU Score: -53.69

Feel that new drugs will push this stock higher in next few minths.

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 1/28/2011 12:47:04 PM : Outperform Start Price: $3.26 IMMU Score: -35.31

Could show solid growth Sling'n them legal life savers and thrills.

Recs

0
Member Avatar LuckyShad (63.54) Submitted: 5/25/2010 3:52:30 PM : Outperform Start Price: $3.29 IMMU Score: -64.52

There were 50 items in your list. Here they are in random order:

1 APOL 2S
CBPO (ALREADY PICKED)
2 AFAM 5S
3 IMMU 3*
4 TNDM 5*
AMED
RAI
VPHM
SNTS
CNU
SOLR
IDCC
HRB
UNTD
UEPS
CHKE
SOHU
DECK
OSK
PDLI
NSR
CBI
LO
CYTK
TTT
JCOM
MHP
CHOP
EME
RGR
CSKI
RTN
UIS
ENDP
PRSC
IPXL
VALU
USMO
ELNK
GME
FWLT
CF
ARO
TSRA
MRX
CBST
PPD
DLX
FLR
LIWA
Timestamp: 2010-05-25 19:32:44 UTC

Recs

0
Member Avatar BullishBilly (31.68) Submitted: 4/10/2010 6:35:07 PM : Outperform Start Price: $3.57 IMMU Score: -55.49

Relative to its industry, it has a high earnings yield. Also, strong earnings per share growth is predicted this year.

Recs

0
Member Avatar rasta999 (< 20) Submitted: 3/23/2010 5:50:51 PM : Outperform Start Price: $3.49 IMMU Score: -57.01

drugs in pipeline

Recs

0
Member Avatar connorsdad418 (20.14) Submitted: 3/10/2010 5:40:53 PM : Outperform Start Price: $3.50 IMMU Score: -60.32

timeframe is a bit long here...i actually believe IMMU will see significant PPS increases about a year sooner but there will be big gains in that four year period overall. greatly situated in the sectors that will see obscene amounts of private and public cash thrown at it, specifically immunotherapy and cancer treatments.

Recs

0
Member Avatar itistime2save (< 20) Submitted: 3/3/2010 10:41:56 PM : Outperform Start Price: $3.37 IMMU Score: -59.59

adding to my position Any opinions?

Recs

0
Member Avatar mrsrmc (< 20) Submitted: 10/16/2009 5:22:58 PM : Outperform Start Price: $4.95 IMMU Score: -99.26

There is a vast underreported and researched arm of health care - auto immune dieases and pain care. Plus factopr in "health care reform" mutant viruses running away with headlines, I think this will be one of the companies perking up into the limelight.

Recs

0
Member Avatar goneskuba (33.12) Submitted: 8/31/2009 4:40:45 PM : Underperform Start Price: $5.39 IMMU Score: +118.22

phase ii trials are a long long way away from late phase iii trials...its appears that HGSI might have gotten the lead on a monclonal SLE drug (HGSI might even get the green light and get fast tracked thru the FDA approval process and to market after this november when they release their data)...it seems that gsk might have actually lost out!!!

All this leaves IMMU in the dust...and one drug a company does not make, esp a drug to market coming in second

Recs

0
Member Avatar stocoptions (< 20) Submitted: 8/27/2009 9:46:31 PM : Outperform Start Price: $6.50 IMMU Score: -125.68

good technology

Recs

0
Member Avatar coachinfool (< 20) Submitted: 8/23/2009 8:18:31 AM : Outperform Start Price: $4.12 IMMU Score: -94.81

No longer using cash to fuel its Bunson burners and has promising results in the pipeline and a fast track approval for hPAM 4.

Recs

0
Member Avatar idahoranch (< 20) Submitted: 6/14/2009 3:08:54 PM : Outperform Start Price: $2.53 IMMU Score: -58.81

Immunomedics hPAM4 antibody for pancreatic cancer is under the radar, but nearly 50% of patients treated in the phase l trial are having good responses with tumors shrinking and the quality of life during and after treatment has been very good, unlike with most Chemo's. This could be a huge home run. The company has stated they have no intention to license this product out.

Also, UCB will be coming out with data for Epratuzumab in their dosing trials for SLE (lupus) where they are trying to find the right dose for the phase lll trials. Every trial done so far has shown Epratuzumab to have efficacy in SLE. Another sleeper.

Recs

0
Member Avatar hmcnamee (< 20) Submitted: 5/12/2009 1:32:56 AM : Outperform Start Price: $1.81 IMMU Score: -6.73

IMMU has moved to profitability over the past two quarters primarily based on the Nycomed deal. They continue to report promising results on a number of other trials for treatments of different forms of cancer. Immunomedics good cash position should provide sufficient funding in the current economic environment. Finally, the company holds an impressive portfolio of patents which seem to be undervalued by the market.

Recs

0
Member Avatar propertiusthesec (< 20) Submitted: 5/27/2008 5:19:12 PM : Outperform Start Price: $2.73 IMMU Score: -7.27

This biotech firm has a portfolio of marketable auction securities that it is selling as opportunities arise; patents and favorable phase two and three tests for drugs that improve the efficacy and reduce the deleterious effects of cancer drugs. It is currently trading above $2.60, and brokerage analysts project that it will trade at $7 within a year. It does seem to be taking a long time for management to negotiate royalty deals with major drug companies, which are said to be interested.

Recs

0
Member Avatar cancunjake (25.94) Submitted: 5/23/2008 5:08:02 PM : Outperform Start Price: $2.36 IMMU Score: +13.58

why not biotechs great place to put money . the use little gasoline

Recs

0
Member Avatar sabrinaa (< 20) Submitted: 5/5/2008 10:45:43 AM : Outperform Start Price: $2.75 IMMU Score: -6.27

will get fda approval

Recs

0
Member Avatar pops83 (20.27) Submitted: 4/2/2008 3:47:58 AM : Underperform Start Price: $2.98 IMMU Score: +20.24

So far I like what I see from the current clinical trial data. Even though I think it will underperform for the next year or so, it looks like a good entry point as far as price of stock. Just because it will probably underperform the 500 does not mean that a profit can't be made. I am sure that as with any biopharm company it will be a rollercoaster ride so I will begin taking positions with "spare change" and build my position gradually.

With biopharm, I look at it as I do when going to Vagas or Biloxi, never take more then I am willing to loose and plan on playing till the plane leaves...............

Translation, never spend it all in one casino, spread it out, make it last, have fun and when the cherries line up, drive it like you stole it!

FOOL ON this one for sure or not?

POPS83

Recs

0
Member Avatar expertlender (< 20) Submitted: 3/26/2008 12:19:08 AM : Outperform Start Price: $2.80 IMMU Score: -15.36

something good maybe

Results 1 - 20 of 30 : 1 2 Next »

Featured Broker Partners


Advertisement